Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
Search results for: hospital
Sonelokimab Promising for Patients with PsA
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
A View from Abroad: The ACR Research Exchange Program
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Type I IFNs in Cutaneous Lupus & Dermatomyositis
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
Meet the Professor: Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a complex, immune-mediated inflammatory disorder characterized by inflammatory back pain and axial arthritis. Typical of other diseases in the spondyloarthritis family, the clinical phenotypes can be diverse, and an array of comorbidities often accompanies the spinal disease. “In this Meet the Professor Session at ACR Convergence 2024,” says Christopher Ritchlin, MD,…
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Interventions to Delay RA Onset
Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
Insight into the ACR’s Commitment to an Inclusive Committee Composition
“While our group carefully considered your application, I regret to inform you that you were not selected this year to serve as a committee volunteer.” When the email arrived, gently delivering the news that my application to volunteer with the ACR on a committee had not been accepted, my initial reaction was to dismiss it…
ACR Convergence 2024 Preview: Key Business Takeaways
In sessions in the business of rheumatology track, rheumatology practice leaders will share ways to manage payer complexities head-on while also improving patient care.
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 317
- Next Page »